2017 has been an active year for AXIM Biotech (OTCQX: AXIM), with a new services agreement and patent filing updates. AXIM entered into a new services agreement with a contract research organization in Israel, focusing on a clinical proof-of-concept study of its Gabapentin and cannabidiol chewing gum product line. The study will test the effectiveness of this product in the treatment of restless leg syndrome.
About Restless Leg Syndrome
Restless leg syndrome, sometimes known as Willis-Ekbom Disease, is a persistent condition that causes irritating sensations in the legs. Sufferers of this syndrome have the unpleasant urge to move their legs, often during the night when they are trying to sleep. The condition often worsens during long periods of inactivity, having a significant effect on the sufferer’s ability to get adequate rest. It is believed that the cause of restless leg syndrome is in the brain, and it can lead …